Vigabatrin


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Infantile spasms
Child: As monotherapy: Initially: 25 mg/kg bid; may adjust in increments of 25-50 mg/kg daily every 3 days, according to clinical response and tolerability. Max: 150 mg/kg daily.

Oral
Refractory complex partial seizures, Resistant partial epilepsy with or without secondary generalisation
Adult: In cases where alternative treatments are inadequate or intolerable: As adjunctive therapy: Initially, 1 g daily as a single or in 2 divided doses; adjust dose in increments of 0.5 g weekly, according to clinical response and tolerability. Max: 3 g daily.
Child: In cases where alternative treatments are inadequate or intolerable: As adjunctive therapy: Initially, 40 mg/kg daily as a single or in 2 divided doses. Maintenance: 10-15 kg: 0.5-1 g daily; 15-30 kg: 1-1.5 g daily; 30-50 kg: 1.5-3 g daily; >50 kg: 2-3 g daily. Dosing recommendations may vary among countries or individual products or preparations. Refer to country- or product-specific recommendations.
Elderly: Initiate at the lower end of the dosing range.
Suy thận
Resistant partial epilepsy with or without secondary generalisation; Refractory complex partial seizures:
CrCl (mL/min)
Dosage
>10-30
Decrease dose by 75%.
>30-50
Decrease dose by 50%.
>50-80
Decrease dose by 25%.
Cách dùng
May be taken with or without food.
Thận trọng
Patient with history of psychosis, depression or behavioural problems; myoclonic seizures. Not indicated as 1st-line agent for complex partial seizures. Not recommended in patients with pre-existing visual field defects. Avoid abrupt withdrawal. Renal impairment. Children and elderly. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Visual field defects, risk for permanent vision loss, anaemia, CNS depression, oedema, peripheral neuropathy, suicidal ideation and behaviour, weight gain.
Eye disorders: Blurred vision, diplopia, nystagmus.
Gastrointestinal disorders: Abdominal pain, nausea, vomiting.
General disorders and administration site conditions: Fatigue, irritability.
Musculoskeletal and connective tissue disorders: Arthralgia.
Nervous system disorders: Somnolence, headache, dizziness, paraesthesia, tremor.
Psychiatric disorders: Agitation, aggression, nervousness, depression, paranoid reaction, insomnia, disturbance in attention and memory impairment.
Skin and subcutaneous tissue disorders: Alopecia.
PO: Z (Insufficient data to conclude its safety and risk during pregnancy. Use only when benefits outweigh risks.)
Thông tin tư vấn bệnh nhân
This drug may cause drowsiness or visual field defects, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Perform ophthalmologic examination (e.g. dilated indirect ophthalmoscopy of the retina, visual acuity, visual field) at baseline (no later than 4 weeks after initiation), periodically (every 3 months) during therapy, and 3-6 months after discontinuation of therapy. Monitor Hb, haematocrit, weight gain, oedema; signs of visual defect, neurotoxicity, peripheral neuropathy, fluid retention. Observe for clinical worsening, suicidality, or unusual changes in behaviour and excessive sedation.
Quá liều
Symptoms: Drowsiness, headache, vertigo, psychosis, bradycardia, agitation, irritability, confusion, abnormal behaviour, speech disorder, hypotension, respiratory depression, coma. Management: Supportive treatment.
Tương tác
May exacerbate sedative effect with clonazepam.
Ảnh hưởng đến kết quả xét nghiệm
May decrease ALT and AST levels. May increase level of amino acids in urine leading to false-positive test for rare genetic metabolic disorder.
Tác dụng
Description: Vigabatrin is a selective irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), resulting in increased levels of the major inhibitory neurotransmitter gamma-aminobutyric acid (GABA) within the brain.
Duration: Variable (dependent on the rate of GABA-T resynthesis).
Pharmacokinetics:
Absorption: Rapidly and completely absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 1 hour.
Distribution: Widely distributed. Crosses the placenta and enters breast milk. Volume of distribution: 1.1 L/kg.
Excretion: Via urine (approx 80%, as unchanged drug). Terminal elimination half-life: Approx 10.5 hours.
Đặc tính

Chemical Structure Image
Vigabatrin

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5665, Vigabatrin. https://pubchem.ncbi.nlm.nih.gov/compound/Vigabatrin. Accessed Oct. 26, 2021.

Bảo quản
Store between 20-25°C.
Phân loại MIMS
Thuốc chống co giật
Phân loại ATC
N03AG04 - vigabatrin ; Belongs to the class of fatty acid derivatives antiepileptic.
Tài liệu tham khảo
Anon. Vigabatrin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/07/2021.

Buckingham R (ed). Vigabatrin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 29/06/2021.

Joint Formulary Committee. Vigabatrin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 29/06/2021.

Kigabeq 500 mg Soluble Tablets (Orphelia Pharma SAS). MHRA. https://products.mhra.gov.uk. Accessed 29/06/2021.

Sabril 500 mg Film-coated Tablets (Aventis Pharma Limited). MHRA. https://products.mhra.gov.uk. Accessed 29/06/2021.

Sabril 500 mg Granules for Oral Solution (Aventis Pharma Limited). MHRA. https://products.mhra.gov.uk. Accessed 29/06/2021.

Sabril 500 mg Tablet (Patheon France S.A.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 29/06/2021.

Sabril Powder for Solution (Lundbeck Pharmaceuticals LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 29/06/2021.

Sabril Tablet, Film Coated (Lundbeck Pharmaceuticals LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 29/06/2021.

Sanofi-Aventis New Zealand Limited. Sabril 500 mg Tablets data sheet 14 September 2020. Medsafe. http://www.medsafe.govt.nz. Accessed 29/06/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Vigabatrin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Sabril
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in